Indivior Pharmaceuticals Accelerates Termination of Copacker Supply Agreement

What Happened Indivior Pharmaceuticals, through its subsidiary Indivior UK Limited, filed an 8-K reporting that on September 9, 2026 it entered a Deed of Variation and Termination with Reckitt Benckiser Healthcare (UK) Limited (RB) to accelerate the termination of the Copacker Supply Agreement (originally dated December 23, 2014; amended March 29, 2019). The agreement will now terminate on January 15, 2027. RB manufactures SUBOXONE® Tablets and SUBUTEX® Tablets for Indivior under that agreement.

Key Details

• Deed effective September 9, 2026; 8-K filed September 15, 2026.
• New accelerated termination date: January 15, 2027.
• RB will manufacture additional units before the new termination date.
• Indivior identified a new supplier; Indivior’s obligations to that supplier become enforceable only after process validation. Indivior says the new supplier agreement is not expected to be material to the parent company.
• Indivior agreed to pay certain costs to RB (lower-volume-related costs, asset disposal and depreciation recovery, redundancy and incentive costs, and potential third‑party costs); aggregate amounts are fixed or capped and “will not be material” to Indivior Pharmaceuticals, Inc.

Why It Matters This filing notifies investors that Indivior is transitioning manufacturing of key branded opioid-dependence products (SUBOXONE® and SUBUTEX® tablets) from Reckitt to a new supplier with a planned exit from the current copacker arrangement by January 15, 2027. The company reports any transition-related charges are capped and not material to the registrant, and production by the new supplier is contingent on validation before contractual obligations begin—details investors should watch for in future updates about manufacturing continuity, inventory plans, and any one-time transition costs.